Another limitation of previous meta-analyses was the inability to standardise between-trial differences in the thresholds of eGFR decrease used to define kidney disease progression within categorical composite outcomes (appendix p 9).1, 6 We therefore performed a collaborative meta-analysis assessing the effects of SGLT2 inhibitors on kidney disease progression according to a standardised outcome definition, and on acute kidney injury, death, heart failure, and key safety outcomes by diabetes status. This evidence concerns the gene SLC5A2 and kidney disorder.